Therapeutic Asset Ratings
6,538 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Obinutuzumab
Richter's Syndrome
Christine Ryan
P2
BB
(71)
Pembrolizumab
Estrogen Receptor Negative
Massachusetts General Hospital
P2
BB
(71)
Pembrolizumab
Progesterone Receptor Negative
Massachusetts General Hospital
P2
BB
(71)
Atezolizumab
Advanced Unresectable or Metastatic Solid Malignancy
UNC Lineberger Comprehensive Cancer Center
P2/3
BB
(71)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Childhood Chronic Myelogenous Leukemia
Diane George
P2/3
BB
(71)
Atezolizumab
Stage IV Lung Cancer AJCC v8
University of Washington
P4
BB
(70)
Cetuximab
Metastatic Colorectal Cancer
Shanghai Henlius Biotech
P4
BB
(70)
Crizanlizumab
Sickle Cell Disease
Novartis Pharmaceuticals
P4
BB
(70)
Donanemab
Alzheimer Disease
Michael Rafii, MD, PhD
P4
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
P4
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Follicular Lymphoma
Sun Yat-sen University
P4
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
HIV Infections
UNC Lineberger Comprehensive Cancer Center
P4
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphoma
City of Hope Medical Center
P4
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mantle Cell Lymphoma
City of Hope Medical Center
P4
BB
(70)
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL17A (INTERLEUKIN 17A, IL-17A)), HOMO SAPIENS MONOCLONAL ANTIBODY
Psoriasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P4
BB
(70)
Nivolumab
Metastatic Melanoma
Bristol-Myers Squibb
P4
BB
(70)
TRASTUZUMAB
HER2-positive Breast Cancer
SWOG Cancer Research Network
P4
BB
(70)
Blinatumomab
Precursor B-Cell Acute Lymphoblastic Leukemia
Amgen
P3
BB
(70)
Cetuximab
Stage IV Colon Cancer
Merck Sharp & Dohme LLC
P3
BB
(70)
Denosumab
Breast Cancer Female NOS
Washington University School of Medicine
P3
BB
(70)
Durvalumab
Locally Advanced Urothelial Carcinoma
Alliance for Clinical Trials in Oncology
P3
BB
(70)
Girentuximab
Kidney Cancer
Memorial Sloan Kettering Cancer Center
P3
BB
(70)
Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 ?1-chain), disulfide with human-Mus musculus monoclonal JMT101 ?-chain, dimer
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc.
P3
BB
(70)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Stage IV Breast Cancer
SWOG Cancer Research Network
P3
BB
(70)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Aggressive B-Cell Non-Hodgkin Lymphoma
Shanghai EpimAb Biotherapeutics Co., Ltd.
P3
BB
(70)
Showing 51 to 75 of 6,538 assets
Previous
Page 3 of 262
Next